Chapple Christopher, Castro-Diaz David, Chuang Yao-Chi, Lee Kyu-Sung, Liao Limin, Liu Shih-Ping, Wang Jianye, Yoo Tag Keun, Chu Romeo, Sumarsono Budiwan
Department of Urology, Royal Hallamshire Hospital, Sheffield, UK.
Department of Urology, Hospital Universitario de Canarias, Universidad de La Laguna, Santa Cruz de Tenerife, Canarias, Spain.
Adv Ther. 2017 Aug;34(8):1953-1965. doi: 10.1007/s12325-017-0577-9. Epub 2017 Jul 7.
Few population-based data are available evaluating the prevalence of lower urinary tract symptoms (LUTS) in Asia. The objective of our study was to determine LUTS prevalence in China, Taiwan, and South Korea using International Continence Society (ICS) 2002 criteria.
An Internet-based self-administered survey among individuals aged at least 40 years with the ability to use a computer and to read the local language. Survey questions included ICS symptom definitions and the international prostate symptom score (IPSS). Data analysis was based on descriptive statistics and post hoc significance testing.
There were 8284 participants, of whom 51% were women and 34% were aged at least 60 years. LUTS prevalence was slightly higher in men than women (62.8% vs. 59.6%; p = 0.004), increasing significantly with age (p = 0.001). All three ICS symptom groups (voiding, storage, and post-micturition) were present in 35% of individuals with LUTS. Symptoms with the highest overall prevalence were nocturia, frequency, incomplete emptying, and terminal dribble. The most bothersome symptoms were terminal dribble, nocturia, and urgency. According to IPSS scores, 87% of participants had at least mild symptoms; 43% of those aged over 60 years had moderate/severe symptoms. The percentage of participants with any LUTS who had visited healthcare professionals because of urinary symptoms was 26%, rising to 45% amongst individuals with all three symptom groups (p = 0.001 vs. other ICS symptom groups).
LUTS are highly prevalent in men and women aged at least 40 years who participated in this study in China, Taiwan, and South Korea and increases with increasing age. A minority of individuals with LUTS seek healthcare and our results suggest an increased patient awareness of LUTS is required.
Astellas Pharma Singapore Pte. Ltd.
ClinicalTrials.gov identifier, NCT02618421.
亚洲地区基于人群评估下尿路症状(LUTS)患病率的数据较少。我们研究的目的是使用国际尿控协会(ICS)2002年标准来确定中国大陆、台湾地区和韩国的LUTS患病率。
对年龄至少40岁、能够使用计算机并阅读当地语言的个体进行基于互联网的自我管理式调查。调查问题包括ICS症状定义和国际前列腺症状评分(IPSS)。数据分析基于描述性统计和事后显著性检验。
共有8284名参与者,其中51%为女性,34%年龄至少60岁。男性的LUTS患病率略高于女性(62.8%对59.6%;p = 0.004),且随年龄显著增加(p = 0.001)。在有LUTS的个体中,35%的人存在ICS的所有三种症状组(排尿期、储尿期和排尿后症状)。总体患病率最高的症状是夜尿、尿频、排尿不尽和尿末滴沥。最困扰人的症状是尿末滴沥、夜尿和尿急。根据IPSS评分,87%的参与者至少有轻度症状;60岁以上的参与者中有43%有中度/重度症状。因尿路症状就诊于医疗专业人员的LUTS患者比例为26%,在存在所有三种症状组的个体中升至45%(与其他ICS症状组相比,p = 0.001)。
在中国大陆、台湾地区和韩国参与本研究的至少40岁的男性和女性中,LUTS非常普遍,且随年龄增长而增加。少数LUTS患者寻求医疗保健,我们的结果表明需要提高患者对LUTS的认识。
阿斯利康制药新加坡私人有限公司。
ClinicalTrials.gov标识符,NCT02618421。